ARATANA THERAPEUTICS, INC. (NASDAQ:PETX) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k

6 years ago

ARATANA THERAPEUTICS, INC. (NASDAQ:PETX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.

On July 16, 2019, Aratana Therapeutics, Inc., a Delaware corporation (the Company), held a special meeting of stockholders (the Special Meeting) to consider certain proposals related to the Agreement and Plan of Merger (the Merger Agreement), dated April 26, 2019, by and among Elanco Animal Health Incorporated, an Indiana corporation (Elanco), Elanco Athens Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco (Acquisition Sub), and the Company, to which, upon the terms and subject to the conditions set forth in the Merger Agreement, Acquisition Sub will merge with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Elanco (the Merger).

As of June 14, 2019, the record date for the Special Meeting, there were 49,002,724 shares of Company common stock outstanding, each of which was entitled to one vote for each proposal at the Special Meeting. At the Special Meeting, a total of 35,769,162 shares of common stock, representing approximately 73.0% of the outstanding shares entitled to vote, were present in person or represented by proxy, constituting a quorum to conduct business.

At the Special Meeting, Company stockholders considered two proposals, each of which is described in more detail in a definitive proxy statement filed by the Company with the Securities and Exchange Commission on June 17, 2019. The final results regarding each proposal are set forth below.

Proposal No. 1: Approval of the Proposal to Adopt the Merger Agreement

The Companys stockholders approved the proposal to adopt the Merger Agreement (the Merger Proposal). The voting results for the Merger Proposal were as follows:

Press Release

On July 16, 2019, the Company issued a press release announcing stockholder approval of the Merger Proposal, which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is filed herewith.

99.1

Press release, dated July 16, 2019

ARATANA THERAPEUTICS, INC. Exhibit
EX-99.1 2 d778779dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Aratana Therapeutics Stockholders Adopt Merger Agreement with Elanco Animal Health Aratana Reports Voting Results from 2019 Special Meeting of Stockholders LEAWOOD,…
To view the full exhibit click here

About ARATANA THERAPEUTICS, INC. (NASDAQ:PETX)

Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.